NASDAQ
08.12.25 | 22:00
21,470 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? | 2 | Investor's Business Daily | ||
| Mo | Nurix stock reaffirmed with Buy rating by Stifel on promising cancer drug data | 4 | Investing.com | ||
| Mo | Nurix reports 75% response rate for bexobrutideg in WM patients | 4 | Investing.com | ||
| Mo | Nurix: Stifel bekräftigt "Buy"-Rating nach vielversprechenden Daten zu Krebsmedikament | 2 | Investing.com Deutsch | ||
| NURIX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition | 1 | GlobeNewswire (USA) | ||
| Sa | Nurix reports 83% response rate for bexobrutideg in CLL patients | 1 | Investing.com | ||
| Sa | Nurix: Bexobrutideg erzielt 83 % Ansprechrate bei Leukämie-Patienten | 4 | Investing.com Deutsch | ||
| Sa | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American ... | 2 | GlobeNewswire (USA) | ||
| 01.12. | Nurix to host webcast on bexobrutideg clinical data next week | 2 | Investing.com | ||
| 10.11. | Nurix Therapeutics beruft ehemaligen Pfizer-Onkologie-Chef in den Verwaltungsrat | 23 | Investing.com Deutsch | ||
| 10.11. | Nurix Therapeutics appoints former Pfizer oncology executive to board | 4 | Investing.com | ||
| 10.11. | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | 129 | GlobeNewswire (Europe) | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| 10.11. | Nurix Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | Nurix reports immune activation data for oral CBL-B inhibitor in cancer | 3 | Investing.com | ||
| 07.11. | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling | 2 | GlobeNewswire (USA) | ||
| 04.11. | 13 Analysts Have This To Say About Nurix Therapeutics | 3 | Benzinga.com | ||
| 03.11. | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 28.10. | Nurix stock price target lowered to $28 at H.C. Wainwright on trial updates | 4 | Investing.com | ||
| 27.10. | Nurix Therapeutics closes $250 million stock offering | 13 | Investing.com | ||
| 27.10. | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock | 1 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
78 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,074 | -3,24 % | EQS-News: Evotec SE: Evotec-Partner Bayer startet Phase-2-Studie zur Behandlung von Patienten mit Alport-Syndrom | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec-Partner Bayer startet Phase-2-Studie zur Behandlung von Patienten mit Alport-Syndrom
04.12.2025 / 08:30 CET/CEST
Für... ► Artikel lesen | |
| MEDIGENE | 0,029 | 0,00 % | MEDIGENE AG stürzt ab - ich warne vor dem nächsten Desaster! | ||
| QIAGEN | 39,665 | -0,31 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| MODERNA | 23,805 | -0,98 % | Moderna-Chef Bancel: "Die vergangenen zwei Jahre waren nicht lustig" | ||
| VALNEVA | 3,826 | -1,85 % | Rheinmetall Aktie: Heiß! - Dt. Börse, Heidelberger Druck, Mutares, Steyr und Valneva im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NOVAVAX | 5,803 | -0,46 % | Novavax, Inc. (NVAX): A Bull Case Theory | ||
| STRYKER | 304,90 | +0,33 % | Stryker Appoints Spencer Stiles As President And COO | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK), Thursday announced the appointment of Spencer Stiles as President and Chief Operating Officer of the company, effective January 1, 2026.Stiles, who... ► Artikel lesen | |
| BIOFRONTERA | 2,620 | -2,96 % | Biofrontera schließt Phase-1-Studie für erweitertes Anwendungsgebiet von Ameluz ab | ||
| ILLUMINA | 109,78 | +0,42 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,000 | +1,21 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| REGENERON PHARMACEUTICALS | 598,20 | -1,03 % | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| BRAIN BIOTECH | 2,930 | -2,33 % | Der Erfolg von Pharvaris freut Brain Biotech | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,790 | -0,56 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,426 | -1,78 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen |
NURIX THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 21,470 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NURIX THERAPEUTICS INC finden Sie auf Wallstreet Online.